Skip to content
value.today

Regado Biosciences Inc

Total raised
$127 M
6 rounds on record
Latest round
$20 M
Feb 2014
First round on record
Dec 2009
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Regado Biosciences Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2014$20 MNo. 6$10 to $50 million

Regado Biosciences Inc: Raise no. 6, Feb 2014

Investors in this round

15 investors had bought by the notice of Feb 25, 2014: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Regado Biosciences Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chris J. Courts · Executive Officer · Vice President of Finance
  • David J. Mazzo · Executive Officer, Director · Chief Executive Officer
  • Michael J. Metzger · Executive Officer · Chief Operating Officer & President
  • Anton J. Gopka · Director
  • B. Jefferson Clark · Director
  • Dennis J. Podlesak · Director · Chairman of the Board
  • Jesse J. Treu · Director
  • Michael J. Mendelsohn · Director
  • P. Sherrill Neff · Director
  • Pierre J. Legault · Director
  • Raphael Jefferson Wisniewski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • BMO Capital Markets Corp. (CRD 16686) · New York, New YorkSold in all US states
  • Cowen and Company, LLC (CRD 7616) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Placement Agent fees equal to 6% of gross proceeds.”

Signed by David J. Mazzo, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 25, 2014. Read the notice at the SEC.

equitySEC
Dec 2012$23 MNo. 5$10 to $50 million

Regado Biosciences Inc: Raise no. 5, Dec 2012

Investors in this round

8 investors had bought by the notice of Jan 17, 2013: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Regado Biosciences Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$23 M of $51 M offered; $28 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Notes are being converted into preferred stock
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J Mazzo · Executive Officer, Director · President and Chief Executive Officer
  • Dennis J. Podlesak · Executive Officer, Director · Chairman of the Board
  • Anton J. Gopka · Director
  • B. Jefferson Clark · Director
  • Jesse J Treu · Director
  • P. Sherrill Neff · Director
  • Raphael Jefferson Wishiewski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David J. Mazzo, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 17, 2013. Read the notice at the SEC.

equitySEC
May 2012$7 MNo. 4$2 to $10 million

Regado Biosciences Inc: Raise no. 4, May 2012

Investors in this round

6 investors had bought by the notice of May 21, 2012: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Regado Biosciences Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $14 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, other: Notes convertible into preferred stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J Mazzo · Executive Officer, Director · President and Chief Executive Officer
  • Dennis Sherrill Podlesak · Executive Officer, Director · Chairman of the Board
  • Jeff Sherrill Clark · Director
  • Jesse J Treu · Director
  • P. Sherrill Neff · Director
  • Raphael Sherrill Wishiewski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David J. Mazzo, President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 21, 2012. Read the notice at the SEC.

equity, debtSEC
May 2011$12 MNo. 3$10 to $50 million

Regado Biosciences Inc: Raise no. 3, May 2011

Investors in this round

8 investors had bought by the notice of Jul 1, 2011: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Regado Biosciences Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series D Preferred Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J Mazzo · Executive Officer, Director · President and Chief Executive Officer
  • Dennis Sherrill Podlesak · Executive Officer, Director · Chairman of the Board
  • Jeff Sherrill Clark · Director
  • Jesse J Treu · Director
  • P. Sherrill Neff · Director
  • Raphael Sherrill Wishiewski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David J. Mazzo, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 1, 2011. Read the notice at the SEC.

equitySEC
Mar 2010$40 MNo. 2$10 to $50 million

Regado Biosciences Inc: Raise no. 2, Mar 2010

Investors in this round

8 investors had bought by the notice of Jul 1, 2011: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Regado Biosciences Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series D Preferred Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J Mazzo · Executive Officer, Director · President and Chief Executive Officer
  • Dennis Sherrill Podlesak · Executive Officer, Director · Chairman of the Board
  • Jeff Sherrill Clark · Director
  • Jesse J Treu · Director
  • P. Sherrill Neff · Director
  • Raphael Sherrill Wishiewski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David J. Mazzo, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 1, 2011. Read the notice at the SEC.

equitySEC
Dec 2009$26 MNo. 1$10 to $50 million

Regado Biosciences Inc: Raise no. 1, Dec 2009

Investors in this round

8 investors had bought by the notice of Jun 30, 2011: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Regado Biosciences Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$26 M of $26 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series D Preferred Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J Mazzo · Executive Officer, Director · President and Chief Executive Officer
  • Dennis Sherrill Podlesak · Executive Officer, Director · Chairman of the Board
  • Jeff Sherrill Clark · Director
  • Jesse J Treu · Director
  • P. Sherrill Neff · Director
  • Raphael Sherrill Wishiewski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David J. Mazzo, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 30, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Regado Biosciences Inc chose not to state its revenue in its newest notice of a funding round (Feb 2014).

    SEC Form D · Feb 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2014

That is all the official record says: Regado Biosciences Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Regado Biosciences Inc
InvestorKindAmountRoundRoleSource
Christopher CourtsPersonnot statednot statedHeld Series D preferred stock (Form 3, 2013)SEC Form 3
Domain Partners VI, L.P.Fund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2013)SEC Form 3
DP VI Associates, L.P.Fund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Edmond De Rothschild Investment PartnersFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Quaker Bioventures Capital LPVenture capitalnot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Quaker Bio Ventures LPVenture capitalnot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2013)SEC Form 3
RMI Investments S.a.r.l.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Robert A. KierlinPersonnot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2013)SEC Form 3
RusnanoMedInvest LLCOthernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 15 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Regado Biosciences Inc
NameRoleNamed in
Chris J. CourtsVice President of FinanceFeb 2014
David J. MazzoChief Executive OfficerFeb 2014
Michael J. MetzgerChief Operating Officer & PresidentFeb 2014
David J MazzoPresident and Chief Executive OfficerJan 2013
Dennis J. PodlesakChairman of the BoardJan 2013
Dennis Sherrill PodlesakChairman of the BoardMay 2012
Dennis J PodlesakChairman of the BoardJan 2010
Anton J. GopkaDirectorFeb 2014
B. Jefferson ClarkDirectorFeb 2014
David J. MazzoChief Executive OfficerFeb 2014
Dennis J. PodlesakChairman of the BoardFeb 2014
Jesse J. TreuDirectorFeb 2014
Michael J. MendelsohnDirectorFeb 2014
P. Sherrill NeffDirectorFeb 2014
Pierre J. LegaultDirectorFeb 2014
Raphael Jefferson WisniewskiDirectorFeb 2014
David J MazzoPresident and Chief Executive OfficerJan 2013
Jesse J TreuDirectorJan 2013
Raphael Jefferson WishiewskiDirectorJan 2013
Dennis Sherrill PodlesakChairman of the BoardMay 2012
Jeff Sherrill ClarkDirectorMay 2012
Raphael Sherrill WishiewskiDirectorMay 2012